This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Nuvilex Subsidiary Austrianova Singapore's Cancer Treatments Featured In Asia's Leading Biotech Industry Magazine

Stocks in this article: NVLX

SILVER SPRING, Md., Aug. 9, 2012 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology provider of cell and gene therapy solutions, announced today an article describing cancer treatments under development by its wholly-owned subsidiary, Austrianova Singapore, has just been published in BioSpectrum Asia, the leading biotechnology industry magazine in Asia.

The invited article entitled " 'Suicide genes' is the next step to cure cancer" was co-authored by Dr. Brian Salmons, Austrianova's President and CEO, and Dr. Walter Gunzburg, its Chairman. The article featured the Company's patented live cell encapsulation technology and pointed to the clinical success in the treatment of solid tumors, among other uses. The use of live encapsulated cells that locally catalyzed conversion of chemotherapeutic prodrugs to their active, cancer-killing forms at the site where they are needed was discussed since it has been shown to work well for pancreatic cancer. In the completed Phase 1/2 clinical trial, patients were noted to experience a doubling of the median survival time through disease improvement or stabilization and an important reduction in the side effects of the added chemotherapy treatment was observed while at the same time enhancing their anti-tumor effectiveness.

The safety and efficacy data obtained from clinical trials of the treatment of pancreatic and breast cancer solid tumors was reviewed in the article. In addition, there was also a discussion of additional preclinical data suggesting improved clinical benefits with fewer side effects than standard chemotherapy were also achievable for tumors such as hepatocellular (liver) cancer, squamous cell carcinoma, ovarian cancer, colon cancer metastases and possibly even brain tumors like glioma/glioblastoma.

Promising preclinical data has already demonstrated use of multiple prodrug activation systems. The data from this ongoing research offers the possibility of "personalized" therapies.  There is even the possibility of combining these treatments with standard radiotherapy to have a greater effect and potential increased success in treating cancer patients.  The article also points out that encapsulated cells can also be used to attack tumors by placing them in the body and allowing continuous production of tumor-honing toxic antibodies, such as Herceptin®. Another means to attack cancer cells can be by placing into the body encapsulated living cells that excrete natural growth inhibitors like tumor necrosis factors (proteins that cause certain cells to die) or anti-angiogenic factors (proteins that inhibit new blood vessel formation). All of these antitumor strategies represent an arsenal that can be combined to attack cancer at many different levels.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,341.36 +272.49 1.60%
S&P 500 2,000.83 +28.09 1.42%
NASDAQ 4,617.6680 +69.8340 1.54%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs